Lassiter Wright III, a director at Quest Diagnostics, has reported a transaction involving the company's common stock. This filing, dated October 23, 2026, highlights his continued investment in the firm, which is significant in the context of the medical laboratories industry.
Background
Quest Diagnostics Inc, identified by the CIK 0001022079, operates in the medical laboratories sector, classified under the SIC code 8071. The company is incorporated in Delaware and has its fiscal year ending on December 31. Recent filings indicate ongoing activity, with the most recent Form 4 submitted on October 23, 2026.
What the Filing Says
The filing reveals that Lassiter Wright III acquired six shares of Quest Diagnostics common stock on October 21, 2026, at a price of $235.959 per share. Following this transaction, he now owns a total of 10,329 shares. The transaction was reported early due to its eligibility for deferred reporting under Rule 16a-6, as noted in the filing.
Impact
This transaction may affect shareholders and potential investors in Quest Diagnostics, as it reflects the confidence and ongoing commitment of its director. Such actions can influence market perceptions and investor sentiment within the medical laboratories sector.
What's Next
The filing does not say what happens next.